GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration.Significant tumor reduction was observed in both administration routes. Both IT and IV were ...

Presenter: Ricky T. Tong, M.D., Ph.D., Clinical Assistant Professor, Lankenau Institute for Medical Research, part of Main Line Health ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

Development of a new nano-immune agonist to improve immunotherapy for melanoma, a challenging skin cancer, by changing the ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric ...

Our body's own defense system not only clears away bacteria and viruses, it can also fight cancer. However, not all tumor ...

A novel approach to tumor-infiltrating lymphocyte therapy yielded higher response rates among patients with metastatic ...

USC researchers have developed an innovative type of cancer-fighting immune cell, the EchoBack CAR T-cell, that uses focused ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

T-cell activation involves two phases, enabling a more precise immune response. This insight may boost cancer immunotherapy ...

Mark Litzow, MD, discusses the challenges of using immunotherapy for the treatment of acute lymphoblastic leukemia.